Skip to main content

Remote Job Finders (RJF)

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Scroll to top